WO2004015422A3 - Diagnostic et traitement de maladies associees au recepteur 1 couple a la proteine g (ogr-1) du cancer de l'ovaire - Google Patents

Diagnostic et traitement de maladies associees au recepteur 1 couple a la proteine g (ogr-1) du cancer de l'ovaire Download PDF

Info

Publication number
WO2004015422A3
WO2004015422A3 PCT/EP2003/008048 EP0308048W WO2004015422A3 WO 2004015422 A3 WO2004015422 A3 WO 2004015422A3 EP 0308048 W EP0308048 W EP 0308048W WO 2004015422 A3 WO2004015422 A3 WO 2004015422A3
Authority
WO
WIPO (PCT)
Prior art keywords
ogr
therapeutics
diagnostics
ovarian cancer
diseases associated
Prior art date
Application number
PCT/EP2003/008048
Other languages
English (en)
Other versions
WO2004015422A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Priority to AU2003266238A priority Critical patent/AU2003266238A1/en
Publication of WO2004015422A2 publication Critical patent/WO2004015422A2/fr
Publication of WO2004015422A3 publication Critical patent/WO2004015422A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un OGR-1 humain associé aux troubles du système nerveux périphérique et central, aux maladies cardio-vasculaires, aux inflammations, aux maladies hématologiques et aux maladies gastro-intestinales. L'invention concerne également des analyses destinées à identifier des composés utilisés dans le traitement ou la prévention de troubles du système nerveux périphérique et central, de maladies cardio-vasculaires, d'inflammations, de maladies hématologiques et de maladies gastro-intestinales. L'invention concerne par ailleurs des composés se liant à et/ou activant ou inhibant l'activité de OGR-1 ainsi que des compositions pharmaceutiques comprenant lesdits composés.
PCT/EP2003/008048 2002-08-05 2003-07-23 Diagnostic et traitement de maladies associees au recepteur 1 couple a la proteine g (ogr-1) du cancer de l'ovaire WO2004015422A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003266238A AU2003266238A1 (en) 2002-08-05 2003-07-23 Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016980 2002-08-05
EP02016980.1 2002-08-05

Publications (2)

Publication Number Publication Date
WO2004015422A2 WO2004015422A2 (fr) 2004-02-19
WO2004015422A3 true WO2004015422A3 (fr) 2004-03-18

Family

ID=31502684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008048 WO2004015422A2 (fr) 2002-08-05 2003-07-23 Diagnostic et traitement de maladies associees au recepteur 1 couple a la proteine g (ogr-1) du cancer de l'ovaire

Country Status (2)

Country Link
AU (1) AU2003266238A1 (fr)
WO (1) WO2004015422A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5292712B2 (ja) * 2007-03-23 2013-09-18 日本電気株式会社 認証連携システム、中継装置、認証連携方法および認証連携プログラム

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834565A2 (fr) * 1996-10-03 1998-04-08 Smithkline Beecham Corporation Un récepteur, HUVCT36, couplé à une protéine G
WO2000006597A2 (fr) * 1998-07-31 2000-02-10 Arena Pharmaceuticals, Inc. Recepteurs orphelins endogenes a activation constitutive couples a la proteine g
WO2002020556A2 (fr) * 2000-09-07 2002-03-14 Genaissance Pharmaceuticals, Inc. Haplotypes du gene gpr68
WO2002024222A2 (fr) * 2000-09-20 2002-03-28 The Cleveland Clinic Foundation Ligands de recepteurs couples a la proteine g et leurs procedes d'utilisation
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2002079438A2 (fr) * 2001-03-29 2002-10-10 Deltagen, Inc. Disruptions du gene ogr1, compositions et procedes associes
WO2003014731A2 (fr) * 2001-08-07 2003-02-20 Euroscreen S.A. Ligand naturel pour le recepteur orphelin couple aux proteines g gpr86 et methodes d'utilisation
WO2003039341A2 (fr) * 2001-11-05 2003-05-15 Millennium Pharmaceuticals, Inc. Procedes et compositions pour traiter des maladies cardio-vasculaires en utilisant 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 ou 93804

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834565A2 (fr) * 1996-10-03 1998-04-08 Smithkline Beecham Corporation Un récepteur, HUVCT36, couplé à une protéine G
WO2000006597A2 (fr) * 1998-07-31 2000-02-10 Arena Pharmaceuticals, Inc. Recepteurs orphelins endogenes a activation constitutive couples a la proteine g
WO2002020556A2 (fr) * 2000-09-07 2002-03-14 Genaissance Pharmaceuticals, Inc. Haplotypes du gene gpr68
WO2002024222A2 (fr) * 2000-09-20 2002-03-28 The Cleveland Clinic Foundation Ligands de recepteurs couples a la proteine g et leurs procedes d'utilisation
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2002079438A2 (fr) * 2001-03-29 2002-10-10 Deltagen, Inc. Disruptions du gene ogr1, compositions et procedes associes
WO2003014731A2 (fr) * 2001-08-07 2003-02-20 Euroscreen S.A. Ligand naturel pour le recepteur orphelin couple aux proteines g gpr86 et methodes d'utilisation
WO2003039341A2 (fr) * 2001-11-05 2003-05-15 Millennium Pharmaceuticals, Inc. Procedes et compositions pour traiter des maladies cardio-vasculaires en utilisant 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 ou 93804

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE SWISS-PROT [online] XP002267249, Database accession no. Q15743 *
HOFFERT C ET AL: "Distribution of ovarian cancer G-protein coupled receptor 1 in human and rat nervous tissue", BIOSIS, XP002209174 *
XU Y ET AL: "SPHINGOSYLPHOSPHORYLCHOLINE IS A LIGAND FOR OVARIAN CANCER G-PROTEIN-COUPLED RECEPTOR 1", NATURE CELL BIOLOGY, MACMILLAN PUBLISHERS, GB, vol. 2, no. 5, May 2000 (2000-05-01), pages 261 - 267, XP008013921, ISSN: 1465-7392 *

Also Published As

Publication number Publication date
AU2003266238A1 (en) 2004-02-25
WO2004015422A2 (fr) 2004-02-19
AU2003266238A8 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2003074069A3 (fr) Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1)
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2003095967A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur 9 des chimiokines (ccr9)
WO2004015422A3 (fr) Diagnostic et traitement de maladies associees au recepteur 1 couple a la proteine g (ogr-1) du cancer de l'ovaire
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2003065044A8 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a gpr72
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2003096020A3 (fr) Diagnostic et traitement de maladies liees au recepteur 8 des chimiokines (ccr8)
WO2004038407A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur 12 humain couple a la proteine g (gpr12)
WO2004015427A3 (fr) Methodes diagnostiques et therapeutiques s'adressant a des maladies associees au recepteur 19 couple a la proteine g (gpr19)
WO2003066077A3 (fr) Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)
WO2004038416A8 (fr) Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)
WO2004042405A3 (fr) Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain
WO2003076945A3 (fr) Diagnostic et therapie de maladies associees au recepteur couple a la proteine g 105 (gpr105)
WO2004038408A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur humain 14 couple a la proteine g (gpr14)
WO2003100433A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 3 de l'arginine vasopressine (avpr3)
WO2003100435A3 (fr) Procede pour diagnostiquer et traiter des maladies associees au recepteur de neuromedine u2 (nmu2)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2004048978A3 (fr) Procedes pour diagnostiquer et traiter des maladies associees au recepteur 37 couple a la proteine g d'acide biliaire (bg37)
WO2005040790A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 75 couple a la proteine g (gpr75)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP